Stone Run Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $857K | Hold |
3,700
| – | – | 0.34% | 47 |
|
|
2025
Q2 | $687K | Sell |
3,700
-400
| -10% | -$74.3K | 0.27% | 48 |
|
|
2025
Q1 | $859K | Hold |
4,100
| – | – | 0.36% | 49 |
|
|
2024
Q4 | $729K | Hold |
4,100
| – | – | 0.29% | 48 |
|
|
2024
Q3 | $810K | Sell |
4,100
-500
| -11% | -$93.3K | 0.3% | 48 |
|
|
2024
Q2 | $789K | Sell |
4,600
-400
| -8% | -$66.3K | 0.32% | 48 |
|
|
2024
Q1 | $911K | Buy |
5,000
+1,300
| +35% | +$224K | 0.35% | 48 |
|
|
2023
Q4 | $573K | Sell |
3,700
-700
| -16% | -$102K | 0.25% | 47 |
|
|
2023
Q3 | $656K | Hold |
4,400
| – | – | 0.32% | 42 |
|
|
2023
Q2 | $593K | Buy |
4,400
+200
| +5% | +$29.3K | 0.26% | 43 |
|
|
2023
Q1 | $669K | Buy |
4,200
+100
| +2% | +$15.3K | 0.32% | 41 |
|
|
2022
Q4 | $663K | Buy |
4,100
+100
| +3% | +$15.3K | 0.33% | 43 |
|
|
2022
Q3 | $537K | Hold |
4,000
| – | – | 0.29% | 41 |
|
|
2022
Q2 | $612K | Sell |
4,000
-700
| -15% | -$107K | 0.31% | 44 |
|
|
2022
Q1 | $761K | Hold |
4,700
| – | – | 0.28% | 44 |
|
|
2021
Q4 | $637K | Hold |
4,700
| – | – | 0.21% | 46 |
|
|
2021
Q3 | $507K | Hold |
4,700
| – | – | 0.17% | 51 |
|
|
2021
Q2 | $530K | Hold |
4,700
| – | – | 0.19% | 51 |
|
|
2021
Q1 | $509K | Hold |
4,700
| – | – | 0.19% | 51 |
|
|
2020
Q4 | $504K | Hold |
4,700
| – | – | 0.2% | 47 |
|
|
2020
Q3 | $411K | Hold |
4,700
| – | – | 0.19% | 51 |
|
|
2020
Q2 | $462K | Hold |
4,700
| – | – | 0.23% | 45 |
|
|
2020
Q1 | $358K | Hold |
4,700
| – | – | 0.21% | 54 |
|
|
2019
Q4 | $416K | Sell |
4,700
-100
| -2% | -$8.3K | 0.18% | 51 |
|
|
2019
Q3 | $363K | Hold |
4,800
| – | – | 0.17% | 51 |
|
|
2019
Q2 | $349K | Sell |
4,800
-50
| -1% | -$3.93K | 0.16% | 54 |
|
|
2019
Q1 | $390K | Hold |
4,850
| – | – | 0.19% | 52 |
|
|
2018
Q4 | $447K | Buy |
4,850
+800
| +20% | +$70.4K | 0.28% | 46 |
|
|
2018
Q3 | $383K | Hold |
4,050
| – | – | 0.18% | 58 |
|
|
2018
Q2 | $375K | Hold |
4,050
| – | – | 0.2% | 55 |
|
|
2018
Q1 | $383K | Sell |
4,050
-250
| -6% | -$27.5K | 0.2% | 53 |
|
|
2017
Q4 | $416K | Hold |
4,300
| – | – | 0.21% | 57 |
|
|
2017
Q3 | $382K | Hold |
4,300
| – | – | 0.2% | 60 |
|
|
2017
Q2 | $312K | Hold |
4,300
| – | – | 0.17% | 62 |
|
|
2017
Q1 | $280K | Hold |
4,300
| – | – | 0.17% | 61 |
|
|
2016
Q4 | $270K | Hold |
4,300
| – | – | 0.18% | 60 |
|
|
2016
Q3 | $271K | Hold |
4,300
| – | – | 0.17% | 62 |
|
|
2016
Q2 | $266K | Buy |
+4,300
| New | +$262K | 0.17% | 62 |
|
|
2015
Q3 | – | Sell |
-4,300
| Closed | -$289K | – | 66 |
|
|
2015
Q2 | $289K | Buy |
+4,300
| New | +$281K | 0.19% | 68 |
|
|
2015
Q1 | – | Sell |
-4,300
| Closed | -$281K | – | 83 |
|
|
2014
Q4 | $281K | Buy |
+4,300
| New | +$271K | 0.19% | 75 |
|
Other funds holding ABBV
Stone Run Capital's ABBV Position: Q3 2025 in Review
Stone Run Capital held its AbbVie (ABBV) position steady in Q3 2025 at 3,700 shares worth $857K. The position accounts for 0.34% of the portfolio, ranked #47.
Stone Run Capital first reported a position in ABBV in Q4 2014 and has held it in 40 quarters since. The position peaked at $911K in Q1 2024. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.
- Stone Run Capital held 3,700 shares of AbbVie worth $857K as of Q3 2025.
- Stone Run Capital left its AbbVie share count unchanged in Q3 2025.
- AbbVie made up 0.34% of Stone Run Capital's portfolio in Q3 2025, its #47 holding.
- Stone Run Capital first reported a position in AbbVie in Q4 2014 and has held it in 40 quarters since.
- Stone Run Capital's AbbVie position peaked at $911K in Q1 2024.
- 3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.
Based on Stone Run Capital's 13F filing for Q3 2025, filed 14 Nov 2025.